AI Article Synopsis
- The KDIGO 2024 Guidelines for chronic kidney disease (CKD) are a significant update, occurring 12 years after the influential 2012 guidelines.
- These new guidelines emphasize the integration of recent therapies that have shown success in treating CKD and related cardiovascular issues, making them relevant for both children and adults.
- The commentary highlights that despite advancements, the diagnosis and treatment of CKD remain subpar across Europe, suggesting that these guidelines serve as a crucial call to action for improving care in this area.
Article Abstract
The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Guidelines for identification and management of chronic kidney disease (CKD) are a welcome development coming 12 years after the paradigm changing 2012 guidelines. We are living in an unprecedented era in nephrology with novel therapies, including sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists now being proven in multiple randomised controlled clinical trials to reduce both the progression of CKD and cardiovascular morbidity and mortality. The KDIGO 2024 CKD guideline is aimed at a broad audience looking after children and adults with CKD and provide practical and actionable steps to improve care. This commentary reviews the guideline sections pertaining to the evaluation and risk assessment of individuals with CKD from a European perspective. We feel that despite the last guideline being published 12 years ago, and that the assessment of CKD has been emphasized by many other national/international nephrology, cardiology and diabetology guidelines and societies, the diagnosis and treatment of CKD remains poor across Europe. As such the KDIGO 2024 CKD Guidelines should be seen as an urgent call to action to improve diagnosis and care of children and adults with CKD across Europe. We know what we need to do. We now need to get on and do it.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfae209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial Intelligence-Enhanced Electrocardiography for Prediction of Incident Hypertension.
JAMA Cardiol
January 2025
National Heart and Lung Institute, Imperial College London, United Kingdom.
Importance: Hypertension underpins significant global morbidity and mortality. Early lifestyle intervention and treatment are effective in reducing adverse outcomes. Artificial intelligence-enhanced electrocardiography (AI-ECG) has been shown to identify a broad spectrum of subclinical disease and may be useful for predicting incident hypertension.
View Article and Find Full Text PDFCKD-Associated Pruritus is Associated with Greater Use of Antidepressants and Anti-pruritus Medications.
Adv Ther
January 2025
CSL Vifor, Glattbrugg, Switzerland.
Introduction: Chronic kidney disease-associated pruritus (CKD-aP) is a common, yet underdiagnosed condition among patients on hemodialysis. Considering the lack of established treatment pathways, we sought to evaluate the use of antidepressant, systemic antihistamines, or gabapentinoid medications among patients with CKD-aP in the year following pruritus assessment.
Methods: We included 6209 patients on hemodialysis in the analysis.
A standardized care pathway increases optimal dialysis starts.
Am J Manag Care
December 2024
Panoramic Health, 850 W Rio Salado Pkwy, Ste 201, Tempe, AZ 85281. Email:
Objective: To determine whether an intensive value-based care educational program that includes a standardized end-stage renal disease (ESRD) transition pathway would improve the number of optimal starts within Kidney Contracting Entities (KCEs).
Study Design: Retrospective cohort study.
Methods: We recorded optimal starts, defined as the initiation of dialysis without a central venous catheter, and the initial modality type (hemodialysis vs peritoneal dialysis [PD]) in adult Medicare patients in a Comprehensive Kidney Care Contracting program.
The frequency and clinical features of posttransplant pneumonia in solid-organ transplantation recipients: A transplant center experience.
Tuberk Toraks
December 2024
Department of Medical Microbiology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Introduction: In solid-organ transplant (SOT) recipients, while survival rates have improved with immunosuppressive therapies, the risk of opportunistic infections has also increased. This study aimed to evaluate the frequency of pneumonia, identify microbiological factors, investigate diagnostic methods, and analyse prognosis.
Materials And Methods: A retrospective study was conducted to identify adult SOT recipients referred to the pulmonary diseases department with a preliminary pneumonia diagnosis between 2011 and 2019.
Metabolomics reveals alterations in gut-derived uremic toxins and tryptophan metabolism in feline chronic kidney disease.
Vet Q
December 2025
Faculty of Veterinary Medicine, Department of Small Animals, Ghent University, Merelbeke, Belgium.
Chronic Kidney Disease (CKD) is one of the most common conditions affecting felines, yet the metabolic alterations underlying its pathophysiology remain poorly understood, hindering progress in identifying biomarkers and therapeutic targets. This study aimed to provide a comprehensive view of metabolic changes in feline CKD across conserved biochemical pathways and evaluate their progression throughout the disease continuum. Using a multi-biomatrix high-throughput metabolomics approach, serum and urine samples from CKD-affected cats ( = 94) and healthy controls ( = 84) were analyzed with ultra-high-performance liquid chromatography-high-resolution mass spectrometry.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!